Suppliers and packagers for LYNPARZA

LYNPARZA

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Astrazeneca	LYNPARZA	olaparib	TABLET;ORAL	208558	NDA	AstraZeneca Pharmaceuticals LP	0310-0569-12	120 TABLET, FILM COATED in 1 BOTTLE (0310-0569-12)	2017-08-17
Astrazeneca	LYNPARZA	olaparib	TABLET;ORAL	208558	NDA	AstraZeneca Pharmaceuticals LP	0310-0569-60	60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0310-0569-60)	2017-08-17
Astrazeneca	LYNPARZA	olaparib	TABLET;ORAL	208558	NDA	AstraZeneca Pharmaceuticals LP	0310-0578-12	120 TABLET, FILM COATED in 1 BOTTLE (0310-0578-12)	2017-08-17
Astrazeneca	LYNPARZA	olaparib	TABLET;ORAL	208558	NDA	AstraZeneca Pharmaceuticals LP	0310-0578-60	60 TABLET, FILM COATED in 1 BOTTLE (0310-0578-60)	2017-08-17
Astrazeneca	LYNPARZA	olaparib	TABLET;ORAL	208558	NDA	AstraZeneca Pharmaceuticals LP	0310-0668-12	120 TABLET, FILM COATED in 1 BOTTLE (0310-0668-12)	2017-08-17

LYNPARZA Supplier Landscape Analysis

Last updated: February 19, 2026

LYNPARZA (olaparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor used in the treatment of certain types of ovarian, breast, prostate, and pancreatic cancers. Its manufacturing requires a complex supply chain involving multiple active pharmaceutical ingredient (API) suppliers and contract manufacturing organizations (CMOs). This analysis details key suppliers and their roles in the LYNPARZA value chain.

Who Are the Primary API Manufacturers for LYNPARZA?

The primary API manufacturer identified for olaparib is AstraZeneca. AstraZeneca, the co-developer and marketer of LYNPARZA with Merck & Co., is directly involved in the manufacturing of the active pharmaceutical ingredient. While specific details on their internal manufacturing sites or initial raw material sourcing are proprietary, AstraZeneca's direct involvement as the originator company points to their control over initial API production.

Beyond AstraZeneca's direct involvement, the pharmaceutical industry standard involves a network of contract manufacturing organizations (CMOs) that may be utilized for various stages of API synthesis and drug product manufacturing. Specific CMOs contracted for olaparib API production are not publicly disclosed by AstraZeneca or Merck & Co. due to confidentiality agreements and competitive considerations. However, major API manufacturers with expertise in complex small molecule synthesis and the capacity to handle stringent quality controls are typically engaged in such processes.

What Are the Key Components and Raw Materials in LYNPARZA Synthesis?

The synthesis of olaparib is a multi-step chemical process. While the complete synthetic route is proprietary, chemical literature and patent disclosures provide insights into the types of precursors and key intermediates involved. The olaparib molecule is characterized by a phthalazinone core linked to a piperazine moiety.

Key structural components and likely precursor categories include:

• Phthalic Anhydride Derivatives: These are fundamental building blocks for the phthalazinone ring system. Specific substituted phthalic anhydrides are likely used to introduce the necessary functional groups.
• Hydrazine Derivatives: Hydrazine or substituted hydrazines are crucial for forming the phthalazinone ring.
• Piperazine Derivatives: Substituted piperazines form the other major part of the olaparib molecule, connecting to the phthalazinone core.
• Halogenated Aromatic Compounds: These are often used as intermediates to facilitate coupling reactions.
• Catalysts and Reagents: Various catalysts (e.g., palladium catalysts for coupling reactions) and specialized reagents are essential for driving the complex organic synthesis steps.

Example of a likely intermediate class (based on structural analysis and common synthetic strategies for similar molecules):

• 2-(Piperazin-1-yl)ethanol: A likely precursor for introducing the piperazine-ethanol side chain, which is then further functionalized.
• Substituted Phthalazinones: Pre-formed phthalazinone rings with appropriate leaving groups for subsequent coupling.

The sourcing of these raw materials would involve global chemical suppliers specializing in fine chemicals, intermediates, and reagents. The quality and purity of these starting materials are critical for the successful synthesis of a pharmaceutical-grade API.

Which Contract Manufacturing Organizations (CMOs) Are Involved in LYNPARZA Production?

Publicly available information does not definitively name the specific CMOs involved in the manufacturing of LYNPARZA API or its final drug product. Pharmaceutical companies, including AstraZeneca and Merck & Co., maintain strict confidentiality regarding their supply chain partners for competitive and proprietary reasons.

However, based on industry practices for complex small molecule drugs like olaparib, potential CMOs would possess the following capabilities:

• API Synthesis: Large-scale organic synthesis, handling of hazardous materials, purification techniques (chromatography, crystallization), and cGMP compliance.
• Drug Product Manufacturing: Formulation of the API into the final dosage form (tablets), blending, granulation, compression, and packaging.
• Quality Control & Assurance: Robust analytical testing, validation of processes, and adherence to global regulatory standards (FDA, EMA).

Reputable CMOs that often partner with major pharmaceutical companies for small molecule APIs and finished dosage forms include:

• Lonza: Known for its comprehensive pharmaceutical services, including API development and manufacturing.
• Catalent: Offers a wide range of drug substance and drug product manufacturing solutions.
• Thermo Fisher Scientific (Patheon): A significant player in contract drug development and manufacturing.
• WuXi AppTec: Provides integrated R&D and manufacturing services to the pharmaceutical industry.

These companies operate globally and are equipped to handle the complex chemistry and regulatory requirements associated with oncology drugs.

What Are the Regulatory Requirements for LYNPARZA Suppliers?

Suppliers for LYNPARZA must adhere to stringent regulatory requirements to ensure the quality, safety, and efficacy of the final drug product. These requirements are enforced by global health authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national regulatory bodies.

Key regulatory aspects include:

• Current Good Manufacturing Practices (cGMP): All manufacturing facilities, processes, and personnel involved in API and drug product production must comply with cGMP regulations. This covers aspects like facility design, equipment qualification, process validation, raw material control, and record-keeping.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. These confidential documents contain detailed information about the manufacturing process, facilities, quality controls, and stability of the API. Drug product manufacturers then reference these DMFs in their marketing applications.
• Quality Agreements: Formal quality agreements are established between the drug product manufacturer (AstraZeneca/Merck & Co.) and each of its API and component suppliers. These agreements define the responsibilities of each party regarding quality control, change management, audits, and regulatory compliance.
• Impurity Profiling and Control: Suppliers must rigorously control and monitor impurities in raw materials and the API. This includes identifying, quantifying, and setting acceptable limits for known and unknown impurities.
• Change Control: Any significant changes to manufacturing processes, raw material suppliers, or analytical methods must be managed through a formal change control system and may require regulatory notification or approval.
• Audits and Inspections: Regulatory agencies conduct regular inspections of manufacturing facilities to ensure cGMP compliance. Drug product manufacturers also conduct their own audits of their suppliers to verify quality systems and adherence to agreements.
• Supply Chain Security: Measures to ensure the integrity and security of the supply chain are crucial, preventing counterfeiting and ensuring product traceability.

The pharmaceutical supply chain for a drug like LYNPARZA is designed with multiple layers of quality control and regulatory oversight.

How Does the LYNPARZA Supply Chain Mitigate Risks?

The LYNPARZA supply chain employs several strategies to mitigate risks associated with manufacturing, quality, and supply continuity.

Risk Mitigation Strategies:

• Dual Sourcing (Where Applicable): While not always publicly disclosed, pharmaceutical companies often qualify secondary suppliers for critical raw materials or intermediates to prevent single-point failures. This provides redundancy in case of supply disruption from the primary source.
• Robust Quality Management Systems: Strict adherence to cGMP, comprehensive quality agreements with suppliers, and rigorous in-house quality control testing by AstraZeneca and Merck & Co. provide multiple checkpoints to ensure API and drug product quality.
• Supplier Qualification and Auditing: Potential suppliers undergo extensive qualification processes, including on-site audits, to assess their manufacturing capabilities, quality systems, and regulatory compliance before being approved. Regular re-audits are conducted.
• Inventory Management: Maintaining appropriate levels of raw materials, intermediates, and finished goods buffers against minor supply disruptions and allows for a transition period if a supplier issue arises.
• Geographic Diversification of Manufacturing: While not confirmed for LYNPARZA, utilizing manufacturing sites in different geographic regions can reduce the impact of localized events such as natural disasters, political instability, or regional regulatory changes.
• Process Validation and Transfer: Thorough validation of manufacturing processes ensures consistency and reproducibility. Robust processes for technology transfer to new or secondary manufacturing sites are essential for scalability and redundancy.
• Regulatory Compliance Monitoring: Continuous monitoring of evolving regulatory requirements in all target markets ensures that suppliers and manufacturing processes remain compliant, avoiding costly delays or product recalls.
• Contingency Planning: Developing detailed contingency plans for various disruption scenarios (e.g., supplier failure, raw material shortage, quality excursion) allows for a swift and organized response.

These measures are standard practice in the pharmaceutical industry to ensure a reliable supply of critical medicines.

What Are the Key Supply Chain Considerations for LYNPARZA Moving Forward?

Future supply chain considerations for LYNPARZA will likely focus on enhanced efficiency, greater transparency, and resilience in the face of evolving global challenges.

Key Considerations:

• Advanced Analytics and Digitization: Implementing advanced analytics and digital tools for supply chain visibility can enable better demand forecasting, inventory optimization, and proactive identification of potential disruptions. This includes the use of AI and machine learning for predictive analytics.
• Sustainability and Environmental, Social, and Governance (ESG) Factors: Increasing pressure from regulators, investors, and the public will necessitate greater attention to the environmental and social impact of the supply chain. This includes responsible sourcing of raw materials, reduction of waste, and fair labor practices by all suppliers.
• Supply Chain Resilience Post-Pandemic: The COVID-19 pandemic highlighted vulnerabilities in global supply chains. AstraZeneca and Merck & Co. will likely continue to reinforce their supply chains to withstand future pandemics, geopolitical shifts, and other systemic disruptions. This may involve further diversification of suppliers and a review of inventory strategies.
• Cost Optimization: While quality and reliability are paramount, continuous efforts to optimize manufacturing costs without compromising standards will remain a focus. This could involve exploring more efficient synthetic routes or negotiating favorable terms with qualified suppliers.
• Emerging Markets and Localization: As LYNPARZA gains broader market access, considerations for localized manufacturing or sourcing in emerging markets may arise to improve accessibility, reduce lead times, and navigate regional regulatory landscapes more effectively.
• Serialization and Traceability: Enhanced serialization and traceability requirements globally will demand robust systems for tracking drug products from manufacturing to the patient, ensuring authenticity and preventing counterfeits.

These forward-looking considerations will shape the strategic direction of the LYNPARZA supply chain to ensure its continued success and ability to meet patient needs.

Key Takeaways

• AstraZeneca is the primary manufacturer of LYNPARZA API, with Merck & Co. as a co-developer.
• Specific contract manufacturing organizations (CMOs) involved in LYNPARZA production are not publicly disclosed, but leading global CMOs with expertise in complex small molecule synthesis and formulation are likely partners.
• The synthesis of olaparib involves a complex multi-step process requiring precursors such as substituted phthalic anhydrides, hydrazine derivatives, and substituted piperazines.
• Suppliers must adhere to stringent regulatory requirements, including cGMP, and manage through Drug Master Files (DMFs) and quality agreements.
• Risk mitigation strategies include dual sourcing, robust quality management systems, extensive supplier auditing, inventory management, and contingency planning.
• Future supply chain considerations will focus on digitization, sustainability, enhanced resilience, cost optimization, and improved traceability.

FAQs

1. How can I identify the specific CMOs manufacturing LYNPARZA? Specific CMOs are not publicly disclosed due to confidentiality agreements between pharmaceutical companies and their manufacturing partners. Information regarding these relationships is proprietary.

2. What are the primary geographic locations for LYNPARZA API sourcing? The primary API manufacturing is handled by AstraZeneca. The geographic locations of their internal manufacturing facilities or their contracted CMOs for API synthesis are proprietary and not publicly available.

3. Does LYNPARZA use any specialized or patented raw materials? While the core olaparib molecule is patented, the specific raw materials and intermediates used in its synthesis are typically commercially available fine chemicals or custom-synthesized intermediates. Their procurement is subject to quality and cost considerations rather than broad patent restrictions on the raw materials themselves.

4. What happens if a key supplier for LYNPARZA experiences a disruption? Pharmaceutical companies maintain risk mitigation strategies, which may include qualifying secondary suppliers for critical components, maintaining buffer inventories, and having contingency plans in place to transition production to alternative sources with minimal disruption to patient supply.

5. Are there opportunities for new suppliers to enter the LYNPARZA supply chain? Entry for new suppliers is highly regulated and competitive. Any potential supplier must undergo rigorous qualification processes, demonstrate cGMP compliance, possess advanced manufacturing capabilities, and meet strict quality standards. Typically, such opportunities arise when existing supply agreements expire, manufacturing needs change, or diversification strategies are implemented.

---

Citations

[1] AstraZeneca. (n.d.). Our medicines. Retrieved from https://www.astrazeneca.com/our-company/our-products/medicines.html (Note: Specific product details are often not granularly detailed on corporate sites, but this confirms AstraZeneca's role as a developer and marketer). [2] U.S. Food and Drug Administration. (n.d.). cGMP Basics. Retrieved from https://www.fda.gov/training-and-resources/good-manufacturing-practices-gmps/cGMP-basics [3] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-and-development/manufacturing-quality-control/good-manufacturing-practice [4] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/drug-master-files-dmfs/drug-master-files-dmfs [5] Professional Pharmaceutical Supply Chain Management Publications and Industry Standards (General knowledge within the field of pharmaceutical supply chain analysis).